Is vaginal estrogen safe? What the research says, including after breast cancer

Dryness, discomfort, sex that suddenly hurts. These changes have a name, genitourinary syndrome of menopause (GSM), and The Menopause Society says it remains underdiagnosed and undertreated. There's also a treatment that works well for many women: low-dose vaginal estrogen. Yet for years, a scary warning box on the package kept many women from using it, or from even asking. Let's look at what the evidence actually shows.

The short answer

The Menopause Society's 2020 position statement on GSM lists low-dose vaginal estrogen among several safe and effective options, and says the systemic risks printed on product labels are "highly unlikely given minimal systemic absorption." In November 2025 the FDA agreed the old warnings didn't fit and asked manufacturers to remove them from the boxed warning. For women with a history of breast cancer, the answer is more individual, and we cover that in detail below.

Vaginal estrogen isn't the same as HRT

This is the source of most of the confusion. Mayo Clinic explains that systemic estrogen (pills, patches, gels, sprays) travels through the whole body, while low-dose vaginal estrogen, in a cream, tablet or ring, mostly treats vaginal and urinary symptoms because much less estrogen reaches the rest of the body. The NHS adds that vaginal estrogen doesn't treat hot flashes or mood swings. For those, see hot flash relief without hormones or what changed with HRT in 2025.

Why the label used to sound so scary, and what changed

Vaginal estrogen labels have long listed the risks of systemic hormone therapy, even though The Menopause Society says those risks are highly unlikely with such minimal absorption. In November 2025 the FDA asked all manufacturers of menopausal hormone therapy to remove boxed warning language about cardiovascular disease, breast cancer and probable dementia. For local vaginal estrogen, endometrial cancer language came out of the box too (it stays only on systemic estrogen-only products), and the FDA asked that vaginal labels condense their safety information to what's most relevant to local use. In February 2026, the FDA approved the first updated labels, including a topical vaginal estrogen product. Labels are being updated product by product, so the leaflet in your box may still be the older version for a while.

What the research says about the big worries

If you've had breast cancer

This is where we slow down, because the stakes feel highest and the guidance is more nuanced.

• Nonhormonal first. ACOG's committee opinion says nonhormonal approaches, like moisturizers and lubricants, are the first-line choice for urogenital symptoms in women with a history of estrogen-dependent breast cancer.
• Vaginal estrogen when those don't work. ACOG says vaginal estrogen can be reserved for women whose symptoms don't respond to nonhormonal options, with the decision made in coordination with the woman's oncologist and after a clear discussion of risks and benefits.
• What the data show. ACOG states that data do not show an increased risk of cancer recurrence among women using vaginal estrogen for these symptoms, while acknowledging the topic remains debated. A 2024 study in JAMA Oncology of two large UK cohorts totaling more than 49,000 women with breast cancer found no evidence of a higher risk of breast cancer death among vaginal estrogen users. The Menopause Society's 2022 statement also says observational data suggest low-dose vaginal estrogen appears safe for survivors when nonhormonal treatment fails.
• Systemic is different. Mayo Clinic notes that systemic estrogen generally isn't recommended after breast cancer, especially if the cancer was hormone sensitive.

Your oncology team knows your cancer type and your treatment plan, which is why this decision belongs with them.

Do you need progesterone with vaginal estrogen?

Generally, no. The Menopause Society says a progestogen isn't recommended with low-dose vaginal estrogen, and routine endometrial checks aren't needed for women without symptoms. The NHS agrees you can use it without a progestogen even if you still have a uterus. Women at higher risk of endometrial cancer may need monitoring, and any spotting or bleeding after menopause needs a thorough evaluation.

How long can you use it?

The Menopause Society says treatment can continue, with appropriate follow-up, for as long as bothersome symptoms are present, and that vaginal estrogen may be used at any age and for an extended duration if needed.

If you'd rather not use estrogen

Mayo Clinic lists several alternatives: vaginal moisturizers used every few days, water- or silicone-based lubricants for sex, vaginal dilators, a nightly vaginal DHEA insert for painful sex, and a daily pill called ospemifene for moderate to severe painful sex. Your clinician can help you sort out which fits your history.

When to call your clinician

• Any vaginal bleeding or spotting after menopause.
• Burning or pain when you pee, or a fever.
• Pain with sex that's getting worse despite treatment.
• Itching, burning or irritation that started after a new product.
• A new breast lump or change, whatever you're using.

Questions to ask your clinician

1. Are my symptoms consistent with genitourinary syndrome of menopause?
2. Would a cream, tablet or ring suit me best, and how often would I use it?
3. Given my personal and family history, are there reasons I shouldn't use vaginal estrogen?
4. If I've had breast cancer: can we loop in my oncologist, and should I try nonhormonal options first?
5. How will we check whether it's working, and when should I follow up?

Talking about vaginal symptoms out loud can feel awkward. Our doctor visit playbook gives you words that make it easier.

Questions

Does vaginal estrogen increase breast cancer risk?

For women without a history of breast cancer, current evidence is reassuring. In the Nurses' Health Study, vaginal estrogen users had no significant difference in overall cancer risk compared with non-users, and Mayo Clinic says small doses are unlikely to raise breast cancer risk.

Can breast cancer survivors use vaginal estrogen?

Sometimes. ACOG recommends nonhormonal options first, with vaginal estrogen considered if those don't work, decided together with your oncologist. ACOG says data do not show an increased recurrence risk, and a 2024 study of over 49,000 women found no evidence of higher breast cancer death.

Did the FDA remove the black box warning on vaginal estrogen?

In November 2025 the FDA asked manufacturers to remove boxed warning language on heart disease, breast cancer, dementia and, for vaginal products, endometrial cancer. The first updated labels, including a vaginal estrogen product, were approved in February 2026, and others are following product by product.

Is it safe to use vaginal estrogen long term?

The Menopause Society says treatment can continue with follow-up for as long as symptoms are bothersome, and may be used at any age and for extended periods if needed. Trial data on the uterus go to 1 year, with reassuring observational data beyond that.

Do I need progesterone with vaginal estrogen?

Generally no. The Menopause Society and the NHS say low-dose vaginal estrogen can be used without a progestogen, even with a uterus. Any bleeding after menopause should still be checked.

Keep reading

• Testosterone for women in menopause: what it can (and can't) do for low libido
• Perimenopause heart palpitations: why your heart races at night, and when to worry
• Menopause joint pain: why your joints ache in perimenopause, and what helps
• Menopause hair loss: why your hair is thinning, and what actually helps
• Heavy periods in perimenopause: flooding, clots, and when to worry
• Perimenopause brain fog: why your memory feels off, and what helps

Education and personal experience, not medical advice. Talk with your own clinician before making health decisions.